二磷酸腺苷P2Y12受体阻断剂的进展与临床应用评价  

Progress and Clinical Application Evaluation on Adenosine Diphosphate P2Y12 Receptor Antagonists

作　　者：张石革[1] 

机构地区：[1]北京积水潭医院,北京大学第四临床医学院药剂科,北京100035

出　　处：《中国医院用药评价与分析》2012年第6期490-495,共6页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的:抗血小板药围绕血栓形成机制,对血小板聚集各个环节进行抑制而成为对抗血栓和心血管事件的一线用药,受到临床和患者的青睐,本文总结二磷酸腺苷(ADP)P2Y12受体阻断剂的研究进展与临床评价。方法:采用国内、外文献综述方法。结果与结论:在大量临床研究中,ADP-P2Y12受体阻断剂显示了良好的疗效,其可选择性、不可逆地抑制ADP所诱导的血小板聚集,各种临床结果已被多项循证医学的系统研究所证实。对于冠状动脉介入治疗前的急性冠状动脉综合征者,ADP-P2Y12阻断剂可使患者死亡、非致死性心肌梗死、非致死性脑卒中的发生率降低。OBJECTIVE： Antiplatelet drug is a member of pharmaceuticals that inhibit thrombus formation anddecrease platelet aggregation and it has become the first line drug against thrombus formation and cardiovascular events that favored by both clinician and patients. This paper summarized the progress and clinical application evaluation of antiplatelet drug adenosine diphosphate P2Y12 receptor antagonists. METHODS： We reviewed the pertinent literature both at home and abroad. RESULTS ＆ CONCLUSION： Large numbers of clinical studies have proved the efficacy of adenosine diphosphate P2Y12 receptor antagonist, its selectivity and ability to irreversibly inhibit adenosine diphosphate-mediated platelet aggregation. These results of clinical trials have been confirmed by multiple evidence- based clinical systematic researches. It can reduce the incidence of death from cardiovascular causes, nonfatal myocardial infarction and nonfatal stroke in patients with acute coronary syndrome prior to undergoing percutaneous coronary intervention, which signifies a new milestone.

关 键 词：抗血小板药 急性冠状动脉综合征 血小板聚集 二磷酸腺苷P2Y12受体阻断剂 

分 类 号：R973[医药卫生—药品]